Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab in Relapsed or Refractory Multiple Myeloma
NCT03275103Phase 1Completed
- Sponsor
- Genentech
- Start
- Sep 2017
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of cevostamab in multiple myeloma (MM), sponsored by Genentech. Primary endpoints: Percentage of Participants with Adverse Events at 8 years, Percentage of Participants With Dose-Limiting Toxicities at 8 years and 1 more. Started Sep 2017; status: completed.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03275103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275103.